Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jul 1;129(13):1952.
doi: 10.1002/cncr.34884.

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Mary Beth Nierengarten
Free article
Comment

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Mary Beth Nierengarten. Cancer. .
Free article
No abstract available

PubMed Disclaimer

Comment on

  • Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
    Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Patel SP, et al. N Engl J Med. 2023 Mar 2;388(9):813-823. doi: 10.1056/NEJMoa2211437. N Engl J Med. 2023. PMID: 36856617 Free PMC article. Clinical Trial.

References

    1. Patel SP , Othus M , Chen Y , et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med . 2023;388(9):813-823. doi:10.1056/nejmoa2211437
    1. Lucas M , Lijnsvelt J , Pulleman S , et al. The NADINA trial: a multicenter, randomized, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. Poster presented at: 2022 ASCO Annual Meeting I; June 2, 2022; Chicago, IL. Session Abstract TPS9605.

LinkOut - more resources